Event: ELCC 2021

0:02:49

The rollout of genomic hubs in the UK

0:02:55

Limitations of genetic testing for actionable mutations in lung cancer

0:04:06

Mesothelioma: how will novel immunotherapies impact surgery?

0:06:13

Systemic treatment of non-oncogene addicted NSCLC with brain metastases

1:40:25

THE PUBLIC ADVANTAGE OF EARLY LEARNING AND CHILD CARE

0:01:49

SCLC hyperprogression with nivolumab

0:04:29

Dr Rushabh Kothari | Prospective analysis of patients with non small cell lung cancer NSCLC

1:07:11

Webinar: Redefining Resource Adequacy for Modern Power Systems

0:03:03

KEYNOTE-799: pembro + chemoradiotherapy in locally advanced NSCLC

0:55:08

Facilitating Engaging Online Discussions

0:01:35

NSCLC: identifying patients most likely to relapse

1:01:06

IASLC Webinar: Perioperative Treatment w/Immune Checkpoint Inhibitors in Patients w/Resectable NSCLC

0:04:28

Combining chemotherapy and immunotherapy: key trials in lung cancer

2:14:48

CPUC Webinar on Reliability & Other Filing Requirements for LSE 2022 IRP (April 7, 2022)

0:01:31

IMpower150: efficacy outcomes of atezolizumab addition in pre-treated EGFR-mutated NSCLC

0:02:44

Disease-free survival in IMpower010 trial: adjuvant atezolizumab in NSCLC

1:24:27

2022 Meteorology & Market Design Workshop: Session 4: Dynamic Reserve Applications Panel Discussion

0:00:39

Continuation of ceritinib beyond disease progression in ALK-positive NSCLC

1:42:54

Panel discussion | Dr Naresh Somani | Immunotherapy in stage 3 NSCLC

1:00:32

Webinar: Multi-value Transmission Planning for a Decarbonized Future

0:03:05

Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150

0:01:48

Clinical trial data for TKIs in ALK-rearranged NSCLC

1:53:37

Decarbonization Interim Modeling Update 2021

0:02:31

Transformed SCLC: emerging science on histologic subtype switching